← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Fimbrion Therapeutics, Inc.
Saint Louis, MO
$7,880,954
Total funding
9
Grants
Funding over time
peak $1.6M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,880,954 · 9
By mechanism
R44$4,618,884 · 2
R43$3,262,070 · 7
Investigators at Fimbrion Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$1,000,000
R44 · FY2022 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$997,875
R44 · FY2023 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$994,977
R44 · FY2024 · AI
Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs$901,235
R44 · FY2017 · AI
Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs$724,797
R44 · FY2018 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria$300,001
R43 · FY2025 · AI
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections$300,000
R43 · FY2023 · AI
Anti-virulence FimH inhibitors for the treatment and prevention of UTIs$300,000
R43 · FY2014 · AI
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections$300,000
R43 · FY2024 · AI
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis$300,000
R43 · FY2024 · AI
Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections$300,000
R43 · FY2025 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$300,000
R43 · FY2020 · AI
Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis$300,000
R43 · FY2025 · AI
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis$300,000
R43 · FY2023 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$293,050
R43 · FY2021 · AI
Anti-virulence FimH inhibitors for the treatment and prevention of UTIs$269,019
R43 · FY2015 · AI